Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (BPTH) Q1 23

Dallas, Texas--(Newsfile Corp. - June 2, 2023) - Bio-Path Holdings, Inc. (NASDAQ: BPTH): Stonegate Capital Partners updates coverage on Bio-Path Holdings, Inc. (NASDAQ: BPTH). The full report can be accessed by clicking on the following link: BPTH Q1 23 Report

To view the full announcement, including downloadable images, bios, and more, click here.

Key Takeaways:

• Owning the Breakthrough Technology: proprietary antisense and liposome delivery technology for DNA drugs
• Strategic Relationships: platform licensed from MD Anderson Cancer Center; BPTH maintains strong relationshipwith the cancer centers
• Strong IP Position: composition of matter and method patents for antisense targets and manufacturing

Click image above to view full announcement.

About Stonegate Capital Partners
Stonegate Capital Partners is a leading capital markets advisory firm providing investor relations, equity research, and institutional investor outreach services for public companies. Our affiliate, Stonegate Capital Markets (member FINRA) provides a full spectrum of investment banking, equity research and capital raising for public and private companies.

Contacts:

Stonegate Capital Partners
(214) 987-4121
[email protected]

Source: Stonegate, Inc.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/168587

You May Also Be Interested In

• Shenzhen Municipal Bureau of Planning and Natural Resources Releases the Urban Index of Shenzhen (UIS) Report, UIS Product Suite Officially Launched Globally
• ENGI Products LLC Releases The Physics of Capital Framework for Industrial Organizations
• IQExit Appoints Former Schwab, Fidelity and Ameriprise Executive Glenn Flego to Board